U Of U Hospitals & Clinics
- Type
- Teaching hospital
- Where
- Salt Lake City, UT
- Medicare CCN
- 460009
- Received
- $25,374,881 in 1,420 records, 2022 ($2,552,495 general, $22,822,386 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 149 | $2,552,495 |
| 2022 | Research payment | 1,271 | $22,822,386 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,271 | $22,822,386 |
| Grant | 32 | $1,765,738 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 12 | $297,620 |
| Space rental or facility fees (teaching hospital only) | 44 | $171,245 |
| Consulting Fee | 8 | $108,321 |
| Long term medical supply or device loan | 18 | $98,300 |
| Education | 7 | $62,500 |
| Charitable Contribution | 17 | $18,994 |
| Royalty or License | 4 | $18,000 |
| Debt forgiveness | 7 | $11,775 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Merck Sharp & Dohme LLC | $256,040 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $167,289 | Research payment | Cash or cash equivalent | Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus P | 2022 |
| 2022-12-31 | SPR Therapeutics, Inc | $81,291 | Research payment | Cash or cash equivalent | SPRINT PNS System Device, Pain Management | A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Back | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $73,104 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $59,777 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamid | 2022 |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $55,818 | Research payment | In-kind items and services | Multitom Rax Device, DI - X-Ray Products | Value of 3D imaging features of Multitom RAX for extremities | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $47,696 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $42,747 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA- | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $32,334 | Research payment | In-kind items and services | A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Posit | 2022 | |
| 2022-12-31 | Soleno Therapeutics, Inc. | $31,421 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $27,832 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Health | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $21,354 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $21,354 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Intuitive Surgical, Inc. | $16,850 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $16,355 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, an | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $12,681 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $10,439 | Research payment | In-kind items and services | FASENRA Biological, Respiratory | A Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study to Investigate the Use of Benralizumab | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $10,244 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | 2022 |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $9,981 | Research payment | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $9,962 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $9,880 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2022 |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $8,719 | Research payment | In-kind items and services | Utah2021MRIPR932IPR941Parker | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,761 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-31 | AstraZeneca UK Limited | $7,351 | Research payment | In-kind items and services | FASENRA Biological, Respiratory | A Multicentre Randomised Double-blind Parallel-group Placebo-controlled 24-week Phase 3 Study with an Open-label Extensi | 2022 |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $6,750 | Research payment | In-kind items and services | MAGNETOM Prisma Device, MR - MRI | UtahDibellaCardioSoftwarePerfMR | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,624 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,033 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab in P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,886 | Research payment | In-kind items and services | Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,758 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2022 |
| 2022-12-31 | PFIZER INC. | $5,611 | Research payment | Cash or cash equivalent | A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTE | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,286 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,227 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, an | 2022 |
| 2022-12-31 | FUJIFILM SonoSite, Inc. | $5,018 | Long term medical supply or device loan | In-kind items and services | PX Ultrasound System Device, Medical Device | 2022 | |
| 2022-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,125 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,028 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $3,985 | Research payment | In-kind items and services | FASENRA Biological, Respiratory | A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Sa | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,965 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or | 2022 |
| 2022-12-31 | Stryker Corporation | $3,945 | Long term medical supply or device loan | In-kind items and services | EZOUT Device, SURGICAL | 2022 | |
| 2022-12-31 | Stryker Corporation | $3,726 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Intuitive Surgical, Inc. | $3,400 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,360 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,906 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-31 | Stryker Corporation | $2,656 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | ABBVIE INC. | $2,465 | Research payment | In-kind items and services | A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Sma | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,197 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2022 |
| 2022-12-31 | ABBVIE INC. | $2,160 | Research payment | In-kind items and services | Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Patients Undergoing Open | 2022 | |
| 2022-12-31 | ABBVIE INC. | $2,160 | Research payment | In-kind items and services | Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Patients Undergoing Open | 2022 | |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $1,875 | Research payment | In-kind items and services | Utah2020MRIPR794Parker | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,728 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with | 2022 |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $1,705 | Research payment | In-kind items and services | Utah2022MRIPR816Kim | 2022 | |
| 2022-12-31 | ABBVIE INC. | $1,581 | Research payment | In-kind items and services | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,407 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Health | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,309 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA- | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,290 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-1 | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,225 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,054 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or | 2022 |
| 2022-12-31 | Philips North America LLC | $1,020 | Long term medical supply or device loan | In-kind items and services | (8269) DreamStation Cpap Device, Medical Device | 2022 | |
| 2022-12-31 | Philips North America LLC | $1,020 | Long term medical supply or device loan | In-kind items and services | (8269) DreamStation Cpap Device, Medical Device | 2022 | |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $938 | Research payment | In-kind items and services | Utah2019MRiPR794Parker | 2022 | |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $825 | Research payment | In-kind items and services | Utah2019MRIPR1092Parker | 2022 | |
| 2022-12-31 | ABBVIE INC. | $811 | Research payment | In-kind items and services | Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Pa | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $630 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Health | 2022 |
| 2022-12-31 | ABBVIE INC. | $556 | Research payment | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $450 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2022 |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $375 | Research payment | In-kind items and services | Utah2021MRIPR0391106Kholmovski | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $364 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II Trial of Pembrolizumab MK-3475 in Subjects with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-1 | 2022 |
| 2022-12-31 | Stryker Corporation | $358 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $262 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,1b, Open label Clinical Study of Intratumoral,Intralesional Administration of V938 in Combination with Pembrol | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $221 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Health | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $149 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $136 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Stryker Corporation | $106 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $82 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase I, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Sub | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $22 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refracto | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab in P | 2022 |
| 2022-12-30 | PFIZER INC. | $16,048 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2022 | |
| 2022-12-28 | United Therapeutics Corporation | $11,338 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2022 |
| 2022-12-23 | Blue Earth Diagnostics | $4,074 | Research payment | Cash or cash equivalent | Axumin Drug, Diagnostic Imaging | An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criter | 2022 |
| 2022-12-23 | Blue Earth Diagnostics | $2,499 | Research payment | Cash or cash equivalent | Axumin Drug, Diagnostic Imaging | An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criter | 2022 |
| 2022-12-22 | Stryker Corporation | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VSP SYSTEM, VSP CRANIAL Device, CRANIOMAXILLOFACIAL | 2022 | |
| 2022-12-22 | JAZZ PHARMACEUTICALS INC. | $1,365 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EXPERIENCE OF PATIENTS WITH SMALL-CELL LUNG CANCER (SCLC) ON SECOND-LINE TREATMENT | 2022 |
| 2022-12-22 | Stryker Corporation | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VSP SYSTEM, VSP CRANIAL Device, CRANIOMAXILLOFACIAL | 2022 | |
| 2022-12-21 | Merck Sharp & Dohme LLC | $192,255 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2022 |
| 2022-12-21 | Blueprint Medicines Corporation | $101,479 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2022 | |
| 2022-12-21 | AstraZeneca Pharmaceuticals LP | $43,000 | Research payment | Cash or cash equivalent | A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group | 2022 | |
| 2022-12-21 | LivaNova USA, Inc. | $1,000 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-12-21 | LivaNova USA, Inc. | $1,000 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-12-21 | Regeneron Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2022 |
| 2022-12-20 | Radius Health, Inc. | $10,500 | Research payment | Cash or cash equivalent | A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $34 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $32 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $27 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $22 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $22 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $16 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $11 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $4 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $3 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-20 | Sarepta Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | SRP-9001-301 | 2022 | |
| 2022-12-19 | Merck Sharp & Dohme LLC | $26,867 | Research payment | Cash or cash equivalent | GARDASIL 9 Biological, VACCINE | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA- | 2022 |
| 2022-12-19 | Boston Scientific Corporation | $9,456 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | AUSCO | 2022 |
| 2022-12-19 | Exelixis Inc. | $8,190 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-12-19 | Medtronic, Inc. | $3,996 | Research payment | Cash or cash equivalent | BIS Device, Brain Monitoring | BIS Sedation w Inhale | 2022 |
| 2022-12-19 | Exelixis Inc. | $2,800 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-12-19 | Exelixis Inc. | $2,500 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-12-19 | Exelixis Inc. | $2,500 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-12-19 | Exelixis Inc. | $2,500 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-12-19 | Exelixis Inc. | $2,451 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-12-19 | Exelixis Inc. | $800 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-12-19 | Exelixis Inc. | $501 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-12-16 | Merck Sharp & Dohme LLC | $59,937 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamid | 2022 |
| 2022-12-16 | PFIZER INC. | $25,660 | Research payment | Cash or cash equivalent | A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTE | 2022 | |
| 2022-12-16 | PFIZER INC. | $23,282 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2022 |
| 2022-12-16 | Takeda Pharmaceuticals U.S.A., Inc. | $18,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-12-16 | Takeda Pharmaceuticals U.S.A., Inc. | $18,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-12-16 | Regeneron Pharmaceuticals, Inc. | $10,080 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A SAFETY AND PHARMACOKINETIC STUDY OF SINGLE AGENT REGN2810 IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR C | 2022 |
| 2022-12-16 | Stryker Corporation | $3,401 | Research payment | Cash or cash equivalent | ACCOLADE Device, HIPS | RADIOGRAPHIC FIXATION OF THE 3D PRINTED TRIDENT II TRITANIUM ACETABULAR SYSTEM IN PRIMARY TOTAL HIP ARTHROPLASTY | 2022 |
| 2022-12-16 | PFIZER INC. | $2,560 | Research payment | Cash or cash equivalent | MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT | 2022 | |
| 2022-12-16 | Stryker Corporation | $1,463 | Research payment | Cash or cash equivalent | TRIDENT Device, HIPS | TRIDENT II ACETABULAR SHELL REVISION STUDY | 2022 |
| 2022-12-16 | LivaNova USA, Inc. | $1,000 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-12-15 | Blueprint Medicines Corporation | $165,297 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2022 | |
| 2022-12-15 | Medtronic, Inc. | $117,844 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | EMBOLISE | 2022 |
| 2022-12-15 | Blueprint Medicines Corporation | $79,080 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2022 | |
| 2022-12-15 | Regeneron Pharmaceuticals, Inc. | $25,328 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2022 |
| 2022-12-15 | Blueprint Medicines Corporation | $15,825 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2022 | |
| 2022-12-15 | Blueprint Medicines Corporation | $12,355 | Research payment | Cash or cash equivalent | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2022 | |
| 2022-12-15 | Blueprint Medicines Corporation | $10,395 | Research payment | Cash or cash equivalent | An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutat | 2022 | |
| 2022-12-15 | Regeneron Pharmaceuticals, Inc. | $10,218 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2022 |
| 2022-12-15 | ABBVIE INC. | $7,358 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multip | 2022 |
| 2022-12-15 | Novo Nordisk AS | $7 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-14 | Exelixis Inc. | $50,377 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | AtezoCab A phase II study of cabozantinib in combination with atezolizumab in patients with metastatic castration-resist | 2022 |
| 2022-12-14 | Exelixis Inc. | $32,322 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | AtezoCab A phase II study of cabozantinib in combination with atezolizumab in patients with metastatic castration-resist | 2022 |
| 2022-12-14 | Merck Sharp & Dohme LLC | $26,744 | Research payment | Cash or cash equivalent | Drug, INFECTIOUS DISEASE | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Health | 2022 |
| 2022-12-14 | Takeda Pharmaceuticals U.S.A., Inc. | $6,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-12-14 | Exelixis Inc. | $3,450 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2022 |
| 2022-12-14 | Exelixis Inc. | $2,981 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2022 |
| 2022-12-14 | Exelixis Inc. | $1,775 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2022 |
| 2022-12-14 | KLS-Martin L.P. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-12-14 | LivaNova USA, Inc. | $1,416 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-12-14 | Exelixis Inc. | $1,365 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2022 |
| 2022-12-14 | Exelixis Inc. | $109 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2022 |
| 2022-12-12 | Merck Sharp & Dohme LLC | $30,076 | Research payment | Cash or cash equivalent | Drug, INFECTIOUS DISEASE | A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, an | 2022 |
| 2022-12-12 | AXOGEN | $7,950 | Research payment | Cash or cash equivalent | Surgical Treatment of Chronic Neuropathic Pain (Rethink-Pain) | 2022 | |
| 2022-12-12 | ARENA PHARMACEUTICALS, INC. | $1,530 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN ADULT SUBJECT | 2022 | |
| 2022-12-11 | VERTEX PHARMACEUTICALS INCORPORATED | $2,786 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With | 2022 | |
| 2022-12-09 | Exelixis Inc. | $8,190 | Research payment | Cash or cash equivalent | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therap | 2022 | |
| 2022-12-09 | Exelixis Inc. | $7,500 | Research payment | Cash or cash equivalent | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therap | 2022 | |
| 2022-12-09 | Exelixis Inc. | $3,300 | Research payment | Cash or cash equivalent | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therap | 2022 | |
| 2022-12-09 | PFIZER INC. | $1,553 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST | 2022 |
| 2022-12-09 | Exelixis Inc. | $562 | Research payment | Cash or cash equivalent | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therap | 2022 | |
| 2022-12-08 | Novartis Pharmaceuticals Corporation | $292,155 | Research payment | Cash or cash equivalent | KISQALI Drug, ONCOLOGY | A PHASE I/II TRIAL OF THE CDK4/6 ANTAGONIST RIBOCICLIB AND THE HDAC INHIBITOR BELINOSTAT IN METASTATIC TRIPLE NEGATIVE B | 2022 |
| 2022-12-08 | Blueprint Medicines Corporation | $42,983 | Research payment | Cash or cash equivalent | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2022 | |
| 2022-12-08 | Medtronic, Inc. | $3,996 | Research payment | Cash or cash equivalent | VIVA XT CRT-D Device, Implantable Cardioverter Defibrillators (ICDs) | AdaptResponse | 2022 |
| 2022-12-08 | Becton, Dickinson and Company | $62 | Charitable Contribution | Cash or cash equivalent | 2022 | ||
| 2022-12-07 | Astellas US Technologies | $367,488 | Research payment | In-kind items and services | Padcev Drug, Oncology | ENCORE A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with | 2022 |
| 2022-12-07 | CSL Behring | $10,360 | Research payment | Cash or cash equivalent | Zemaira Biological, Pulmonary/Respiratory Diseases | A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alp | 2022 |
| 2022-12-07 | PFIZER INC. | $7,293 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2022 | |
| 2022-12-07 | PFIZER INC. | $6,445 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2022 |
| 2022-12-07 | ARENA PHARMACEUTICALS, INC. | $3,510 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN ADULT SUBJECT | 2022 | |
| 2022-12-07 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | Zemaira Biological, Pulmonary/Respiratory Diseases | A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alp | 2022 |
| 2022-12-07 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | Zemaira Biological, Pulmonary/Respiratory Diseases | A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alp | 2022 |
| 2022-12-07 | CSL Behring | $112 | Research payment | Cash or cash equivalent | Zemaira Biological, Pulmonary/Respiratory Diseases | A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alp | 2022 |
| 2022-12-06 | PTC Therapeutics, Inc. | $52,589 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY OF PTC923 IN SUBJECTS WITH PHENYLKETONURIA | 2022 | |
| 2022-12-06 | Boston Scientific Corporation | $5,228 | Research payment | Cash or cash equivalent | Precision Device, PAIN MANAGEMENT | WAVEWRITER SOLIS | 2022 |
| 2022-12-06 | PFIZER INC. | $4,185 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2022 | |
| 2022-12-02 | Merck Sharp & Dohme LLC | $65,720 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2022 |
| 2022-12-02 | Stryker Corporation | $5,550 | Research payment | Cash or cash equivalent | TRIDENT Device, HIPS | RADIOGRAPHIC FIXATION OF THE 3D PRINTED TRIDENT II TRITANIUM ACETABULAR SYSTEM IN PRIMARY TOTAL HIP ARTHROPLASTY | 2022 |
| 2022-12-02 | Optinose US, Inc. | $5,280 | Research payment | Cash or cash equivalent | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa | 2022 | |
| 2022-12-02 | Stryker Corporation | $3,376 | Research payment | Cash or cash equivalent | BIOLOX Device, JOINT REPLACEMENT HIPS, KNEES | RADIOGRAPHIC FIXATION OF THE 3D PRINTED TRIDENT II TRITANIUM ACETABULAR SYSTEM IN PRIMARY TOTAL HIP ARTHROPLASTY | 2022 |
| 2022-12-02 | Becton, Dickinson and Company | $3,000 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-12-02 | PTC Therapeutics, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-12-01 | LivaNova USA, Inc. | $46,908 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-12-01 | PFIZER INC. | $6,330 | Research payment | Cash or cash equivalent | A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTE | 2022 | |
| 2022-12-01 | Medtronic, Inc. | $2,600 | Research payment | Cash or cash equivalent | BIS Device, Brain Monitoring | BIS Sedation w Inhale | 2022 |
| 2022-12-01 | Siemens Medical Solutions USA, Inc. | $2,000 | Royalty or License | Cash or cash equivalent | 2022 | ||
| 2022-12-01 | Rapid Medical Ltd | $1,000 | Research payment | Cash or cash equivalent | COMANECI 17 Device, Neurovascular | Success Study | 2022 |
| 2022-12-01 | Agios Pharmaceuticals, Inc. | $274 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | PyruvateKinase Deficiency Global Longitudinal Registry | 2022 |
| 2022-11-30 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | Zemaira Biological, Pulmonary/Respiratory Diseases | A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alp | 2022 |
| 2022-11-30 | CSL Behring | $686 | Research payment | Cash or cash equivalent | Zemaira Biological, Pulmonary/Respiratory Diseases | A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alp | 2022 |
| 2022-11-30 | CSL Behring | $350 | Research payment | Cash or cash equivalent | Zemaira Biological, Pulmonary/Respiratory Diseases | A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alp | 2022 |
| 2022-11-30 | ABBVIE INC. | $137 | Research payment | Cash or cash equivalent | A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 | 2022 | |
| 2022-11-29 | Chiesi USA, Inc. | $500 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-11-28 | Merck Sharp & Dohme LLC | $460,210 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | 2022 |
| 2022-11-28 | Kite Pharma, Inc. | $34,278 | Research payment | Cash or cash equivalent | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH P | 2022 | |
| 2022-11-23 | ALBIREO PHARMA, INC. | $10,996 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2022 |
| 2022-11-23 | ALBIREO PHARMA, INC. | $7,956 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2022 |
| 2022-11-23 | PFIZER INC. | $4,204 | Research payment | Cash or cash equivalent | A PHASE 12 OPENLABEL MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEPUP PRIMING DOSES AND LONGER DOSING INTE | 2022 | |
| 2022-11-22 | Astellas Pharma Global Development | $15,000 | Research payment | Cash or cash equivalent | Padcev Drug, Oncology | ENCORE: A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with | 2022 |
| 2022-11-22 | Regeneron Pharmaceuticals, Inc. | $2,468 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2022 |
| 2022-11-22 | LivaNova USA, Inc. | $1,232 | Research payment | Cash or cash equivalent | VNS Therapy Symmetry Model 8103 Generator Device, Cardiology/Vascular Diseases | A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Thera | 2022 |
| 2022-11-21 | Exelixis Inc. | $2,862 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-11-21 | Exelixis Inc. | $2,800 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-11-21 | Exelixis Inc. | $2,402 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
| 2022-11-21 | Boston Scientific Corporation | $2,176 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | AUSCO | 2022 |
| 2022-11-21 | Boston Scientific Corporation | $1,188 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2022 |
| 2022-11-21 | Boston Scientific Corporation | $360 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | IT MATTERS | 2022 |
| 2022-11-21 | Exelixis Inc. | $57 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second N | 2022 |
The latest 200 records of 1,420.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Salt Lake City, UT, county Salt Lake County, UT, state Utah; placed by its city name.
| Measure | Place (city or town) Salt Lake City, UT | County Salt Lake County, UT | State Utah |
|---|---|---|---|
| Population B01003 | 208,007 | 1,196,523 | 3,392,331 |
| Population, 2020 census P1 | 199,723 | 1,185,238 | 3,271,616 |
| Median age B01002 | 32.9 | 34.0 | 32.0 |
| Under 18 B01001 | 16.4% | 25.3% | 27.8% |
| 65 and over B01001 | 12.5% | 11.9% | 11.9% |
| Households B11001 | 92,652 | 426,245 | 1,124,822 |
| Foreign born B05002 | 14.9% | 13.5% | 8.9% |
| Median household income B19013 | $75,090 | $97,494 | $95,166 |
| Median family income B19113 | $109,291 | $116,682 | $109,675 |
| Per capita income B19301 | $51,173 | $45,106 | $40,873 |
| Poverty rate B17001 | 13.6% | 8.1% | 8.5% |
| Unemployment rate B23025 | 4.2% | 3.8% | 3.6% |
| Civilian labor force B23025 | 129,830 | 670,900 | 1,778,106 |
| Mean commute (minutes) B08013 | 19.5 | 22.3 | 22.1 |
| Bachelor's degree or higher B15003 | 51.5% | 39.4% | 37.7% |
| Housing units B25001 | 101,188 | 449,662 | 1,223,468 |
| Owner-occupied B25003 | 45.8% | 66.1% | 70.2% |
| Renters B25003 | 54.2% | 33.9% | 29.8% |
| Median home value B25077 | $539,500 | $525,700 | $489,400 |
| Median gross rent B25064 | $1,414 | $1,592 | $1,496 |
| White, not Hispanic B03002 | 64.4% | 66.6% | 74.7% |
| Black B03002 | 2.3% | 1.7% | 1.1% |
| Hispanic or Latino B03002 | 20.8% | 20.6% | 15.9% |
| Asian B03002 | 4.9% | 4.2% | 2.4% |
| American Indian and Alaska Native B03002 | 0.5% | 0.5% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Salt Lake City, UT.
Comments